InsiderSignalSign in

← Insider buys

MRK

Merck & Co., Inc. · Healthcare

Insiders sold $70.7M of Merck & Co., Inc. in the last 12 months and bought none

$0Bought, 12 mo

$70.7MSold, 12 mo

$358.4BMarket cap

MRK over the last year

No insider buys filed in this year

MRK after insider buys

3 months after each buy, from the first price a copier could get.

1 buy has 3 months of prices so far. A record shows here at 3.

Congress

Members reported 127 trades in MRK since 2023.

Every filing

137 insider filings since 2016, newest first

Johannes Jacobus Oosthuizen · Pres, U.S. Market

$4.5M−71.0%Nov 7

Kenneth C Frazier · Exec Chair

$46.4M−40.0%Nov 7

Kenneth C Frazier · Exec Chair

$59.9M−46.0%Nov 3

Sanat Chattopadhyay · Exe V-P, Pres MMD

$10.0M−47.0%Nov 1

Richard R. Deluca · EVP, Pres, Merck Animal Heallt

$16.5M−54.0%Nov 1

Steven Mizell · EVP and CHRO

$2.5M−44.0%Nov 1

Johannes Jacobus Oosthuizen · Pres, U.S. Market

$364K−24.0%Nov 1

Jennifer Zachary · EVP and General Counsel

$16.4M−81.0%Nov 1

Kenneth C Frazier · Exec Chair

$87.1M−55.0%Nov 1

Rita A Karachun · SVP Fince-Global Controller

$3.2M−44.0%Nov 1

Kenneth C Frazier · Exec Chair

$54.6M−53.0%Nov 10

Richard R. Deluca · EVP, Pres, Merck Animal Heallt

$2.7M−20.0%Nov 5

Caroline Litchfield · EVP and CFO

$1.7M−43.0%Nov 5

Rita A Karachun · SVP Fince-Global Controller

$2.2M−41.0%Nov 4

Julie L. Gerberding · EVP and Chief Patient Officer

$8.5M−71.0%Nov 3

Frank Clyburn · EVP, Pres ? Human Health

$3.5M−29.0%Nov 2

Sanat Chattopadhyay · Exe V-P, Pres MMD

$2.1M−21.0%Nov 2

Richard R. Deluca · EVP, Pres, Merck Animal Heallt

$11.9M−53.0%Nov 2

Frank Clyburn · EVP, Pres ? Human Health

$1.5M−17.0%May 11

Kenneth C Frazier · Chair, President and CEO

$22.8M−40.0%Nov 12

Robert M Davis · EVP, Global Svcs, CFO

$20.4M−59.0%Oct 6

Sanat Chattopadhyay · Exe V-P, Pres MMD

$862K−13.0%Aug 17

Frank Clyburn · EVP and Chief Commercial Officer

$1.5M−19.0%Aug 6

Julie L. Gerberding · EVP Strat Comm, GI Pub Policy

$2.9M−58.0%Jul 20

Wendell P Weeks · Director

$380K−98.0%May 7

Leslie A Brun · Director

$377K−72.0%May 7

Julie L. Gerberding · EVP Strat Comm, GI Pub Policy

$9.1M−73.0%Jan 15

Richard R. Deluca · EVP, Pres, Merck Animal Heallt

$3.2M−34.0%Aug 12

Robert M Davis · EVP, Global Svcs, CFO

$18.5M−61.0%Jun 27

Frank Clyburn · EVP and Chief Commercial Officer

$1.9M−27.0%May 9

Richard R. Deluca · EVP, Pres, Merck Animal Heallt

$2.8M−33.0%May 7

Robert M Davis · EVP, Global Svcs, CFO

$15.9M−58.0%Mar 27

Kenneth C Frazier · Chair, President and CEO

$15.8M−19.0%Mar 20

Kenneth C Frazier · Chair, President and CEO

$1.5M−2.0%Mar 14

Kenneth C Frazier · Chair, President and CEO

$1.6M−2.0%Mar 6

Kenneth C Frazier · Chair, President and CEO

$7.7M−12.0%Feb 22

Kenneth C Frazier · Chair, President and CEO

$10.9M−16.0%Feb 19

Sanat Chattopadhyay · Exe V-P, Pres MMD

$5.8M−59.0%Feb 14

Wendell P Weeks · Director

$394K−98.0%Feb 14

Rita A Karachun · SVP Fince-Global Controller

$5.1M−80.0%Feb 14

Leslie A Brun · Director

$236K−61.0%Feb 11

Kenneth C Frazier · Chair, President and CEO

$18.1M−25.0%Feb 6

Thomas H Glocer · Director

$760K−66.0%Feb 4

Julie L. Gerberding · EVP Strat Comm, Gl Pub Policy

$2.7M−44.0%Nov 8

Roger M Perlmutter · Exe V-P, Pres, MRL

$17.0M−61.0%Nov 8

Adam H Schechter · EVP, Pres-Global Human Health

$20.5M−83.0%Nov 2

Richard R. Deluca · EVP, Pres, Merck Animal Health

$1.8M−31.0%Nov 1

Ashley Watson · SVP Chief Ethics, Com Officer

$3.5M−83.0%Nov 1

Kenneth C Frazier · Chair, President and CEO

$20.2M−29.0%Oct 3

Kenneth C Frazier · Chair, President and CEO

$19.6M−29.0%Sep 19

Newer filings Older filings

About Merck & Co., Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.